Investing.com’s stocks of the week By Investing.com

Tech underperformed sharply as the Nasdaq fell more than 4.5% for the week, with rotation into defensive names and Bitcoin’s drop below $60,000 pressuring crypto-linked stocks. Micron was a bright spot, beating fiscal Q3 EPS at $25.11 versus $20.49 consensus and revenue at $41.46B versus $35.69B, while guiding Q4 revenue to $49B-$51B and seeing its target lifted to $2,000. Apple fell 6.4% on reports of 15%-25% price hikes, ON Semiconductor plunged 24% after announcing a roughly $7B Synaptics acquisition, and Strategy dropped more than 28% on Bitcoin weakness, while J&J, Merck, and Lilly gained 7.6%-11.4% on defensive inflows.

Analysis

The key signal is not the individual stock moves but the cross-asset regime shift: capital is leaving duration-sensitive growth and crowding into balance-sheet visibility. That matters because it creates a feedback loop where the most expensive AI/data-center beneficiaries can de-rate even on good fundamentals if passive and quant flows keep rotating toward lower-beta defensives. In that setup, semiconductor winners with clear pricing power can still outperform, but the market will increasingly reward earnings quality over narrative.

Micron’s beat is more important for the group than for the stock itself: it strengthens the argument that memory is entering a multi-quarter upcycle with limited near-term supply response, which should support not only MU but also select equipment and component suppliers that benefit from capex persistence. The second-order risk is that this very strength pulls forward optimism, making the trade vulnerable to any sign of customer inventory normalization or easing lead times over the next 1-2 quarters. If memory ASPs stay elevated, the best expression may be through the supply chain rather than chasing MU after a sharp repricing.

Apple’s price increases and ON’s Synaptics deal both point to margin defense under cost inflation, but in different ways: Apple is passing through input pressure while ON is effectively spending capital to buy complexity and scale. That usually favors quality compounders over serial acquirers, especially when the market is rewarding simplicity and cash generation. The defensive bid into pharma suggests investors are paying for earnings durability, so any rebound in growth will likely need a real rates move lower or a stabilizing crypto/tech tape, not just cheaper valuations.

Key Decisions for Investors

• Long MU / short SOXX for 2-6 weeks: own the best fundamental visibility in memory while hedging broader semi multiple compression; risk/reward improves if the market keeps rotating out of high-duration tech.
• Buy MU call spreads into any 3-5% pullback over the next 1-2 weeks: participate in the memory upcycle without paying full premium after the post-earnings re-rating.
• Short ON vs long a higher-quality analog/equipment basket for 1-3 months: the Synaptics deal adds integration and execution risk; upside is capped unless the market re-prices M&A complexity favorably.
• Use AAPL as a relative short versus JNJ or LLY for 2-8 weeks: margin defense via pricing is a weaker catalyst than durable defensive earnings, especially if the market keeps rewarding low-volatility cash flow.
• Avoid long MSTR/Strategy until BTC reclaims and holds above $60k for multiple sessions: these equities can overshoot on the downside even after the coin stabilizes, offering better entry only after forced-selling pressure abates.